Nektar Therapeutics (NKTR) Stock Price, News & Analysis

Company Overview

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Key Stats

• Today's Range: $1.10 to $1.15
• 50-Day Range: $1.00 to $1.45
• 52-Week Range: $0.46 to $1.93
• Volume: 962,000 shs
• Average Volume: 1.76 million shs
• Market Capitalization: $210.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Moderate Buy

Nektar Therapeutics Stock Analysis - MarketRank™

Nektar Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 180th out of 961 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nektar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nektar Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nektar Therapeutics are expected to decrease in the coming year, from ($0.76) to ($0.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nektar Therapeutics is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nektar Therapeutics is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nektar Therapeutics has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.88% of the float of Nektar Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Nektar Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nektar Therapeutics has recently decreased by 1.91%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nektar Therapeutics does not currently pay a dividend.

Dividend Growth

Nektar Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.77

Percentage of Shares Shorted

2.88% of the float of Nektar Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Nektar Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nektar Therapeutics has recently decreased by 1.91%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.93

News Sentiment

Nektar Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for NKTR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,304.00 in company stock.

Percentage Held by Insiders

Only 3.71% of the stock of Nektar Therapeutics is held by insiders.

Percentage Held by Institutions

75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NKTR Stock Analysis - Frequently Asked Questions

How have NKTR shares performed this year?

Nektar Therapeutics' stock was trading at $0.5650 at the beginning of the year. Since then, NKTR shares have increased by 101.8% and is now trading at $1.14.
View the best growth stocks for 2024 here.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.04. The biopharmaceutical company earned $23.49 million during the quarter, compared to analyst estimates of $17.24 million. Nektar Therapeutics had a negative net margin of 180.70% and a negative trailing twelve-month return on equity of 173.28%.

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' top institutional shareholders include Eventide Asset Management LLC (5.10%), Primecap Management Co. CA (3.21%), Geode Capital Management LLC (2.15%) and State Street Corp (1.81%). Insiders that own company stock include Deep Track Capital, Lp, Howard W Robin, Jillian B Thomsen, Gil M Labrucherie, Mark Andrew Wilson, Robert Chess, Jonathan Zalevsky, Roy A Whitfield, Myriam Curet and John Northcott.
View institutional ownership trends.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nektar Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Exxon Mobil (XOM).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 12/01/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/03/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:NKTR
• CUSIP: 64026810
• CIK: 906709
• Web: www.nektar.com
• Phone: (415) 482-5300
• Fax: 415-339-5300
• Employees: 220
• Year Founded: 1990

Price Target and Rating

• Average Stock Price Target: $3.50
• High Stock Price Target: $7.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +207.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-276,060,000.00
• Net Margins: -180.70%
• Pretax Margin: -180.71%
• Return on Equity: -173.28%
• Return on Assets: -46.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.24
• Quick Ratio: 4.24

Sales & Book Value

• Annual Sales: $90.12 million
• Price / Sales: 2.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.27 per share
• Price / Book: 4.22

Miscellaneous

• Outstanding Shares: 184,460,000
• Free Float: 177,615,000
• Market Cap: $210.28 million
• Optionable: Optionable
• Beta: 0.61